Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction
Tenax Therapeutics Inc. focuses on pulmonary hypertension in the setting of heart failure with preserved left ventricular ejection fraction, addressing a cardiopulmonary condition marked by impaired exercise capacity and elevated pulmonary pressures.
- PH-HFpEF
- Exercise Limitation
- 6-Minute Walk Distance
The clinical program centers on improving functional status and evaluating treatment effects in patients with this overlapping cardiac and pulmonary vascular disorder.
Cardiopulmonary Symptom Management
The sponsor’s research interest includes symptoms and functional impairment associated with pulmonary vascular disease and heart failure, with attention to patient mobility and daily physical performance.
- Functional Capacity
- Dyspnea
- Exercise Tolerance
Its funded activity reflects a therapeutic focus on measurable improvements in activity limitation within a mixed cardiovascular and respiratory disease population.
Oral Inotropic and Vasodilator Therapy
Tenax Therapeutics Inc. is engaged in research on levosimendan, a therapy of interest in cardiopulmonary disease management, with emphasis on treatment options for patients who remain limited by PH-HFpEF.
- Levosimendan
- Oral Therapy
- Hemodynamic Support
The sponsor’s work highlights pharmacologic strategies aimed at improving exertional performance in a complex heart-lung condition.
Clinical Evaluation in Multinational Sites
The company’s trial activity spans multiple collaborating research sites across several countries, supporting clinical investigation in a geographically broad pulmonary hypertension population.
- Multinational Enrollment
- Site Collaboration
- Patient Recruitment
This research footprint is aligned with the assessment of therapies for a specialized cardiovascular indication requiring coordinated clinical access.
